TP53 and glioblastoma: Their study showed that U87 cells, a widely used glioblastoma cell line originally derived from a human GBM tumor, exhibited widespread transcriptional changes to the CB2R inverse agonist AM630, including suppression of cell cycle regulators and activation of immune‐related pathways such as TP53 and interferon signaling.